Basic Information
| LncRNA/CircRNA Name | LINC01133 |
| Synonyms | NA |
| Region | GRCh38_1:159961218-159984750 |
| Ensemble | ENSG00000224259 |
| Refseq | NR_038849 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Luciferase assay |
| Sample | gastric cancer tissues, cell lines (SUN-216, BGC-823, AGS,BGC-803, NUGC4, MKN74, MKN45, SGC-7901, HGC-27, GES-1 ) |
| Expression Pattern | down-regulated |
| Function Description | LINC01133 was downregulated in GC tissues and cell lines. LINC01133 depletion promoted cell proliferation, migration, and the epithelial-mesenchymal transition (EMT) in GC cells. Bioinformatics analysis and luciferase assays revealed that miR-106a-3p was a direct target of LINC01133. Low expression of LINC01133 is positively associated with tumor progression and poor prognosis in GC patients. |
| Pubmed ID | 30134915 |
| Year | 2018 |
| Title | LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/?-catenin pathway. |
External Links
| Links for LINC01133 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |